Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab nasal spray
- Development stage
- Phase 4
- Lead developer
- Hospices Civils de Lyon
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intranasal
01
Overview
Bevacizumab nasal spray is an intranasal formulation of the humanized monoclonal antibody bevacizumab, specifically developed by Hospices Civils de Lyon for the treatment of epistaxis (nosebleeds) in patients with Hereditary Hemorrhagic Telangiectasia (HHT). As an anti-angiogenic agent, bevacizumab binds to and neutralizes human vascular endothelial growth factor (VEGF), thereby inhibiting the interaction with its receptors and suppressing the abnormal angiogenesis and telangiectasia formation characteristic of HHT. The ELLIPSE Phase 1 study demonstrated that the nasal spray was well-tolerated with no detectable systemic absorption; however, subsequent Phase 2/3 clinical trials failed to show a significant reduction in monthly epistaxis duration compared to placebo.
- Brand names
- Avastin
- Other names
- bevacizumab nasal sprayELLIPSE study drug
02
Targets
Beyond the preview
Go deeper on bevacizumab nasal spray.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab nasal spray.